It is expected that NSCLC patients with EGFR-driven disease will show a substantial PFS advantage over patients with both EGFR and MET-driven disease (as evidenced by lower EGFR/MET relative ratios; continuous variable) when treated with EGFR inhibitors. This evidence concerns the gene MET and non-small cell lung carcinoma.